The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ISHL12 2022 | Using PET-adapted study designs to de-escalate treatment intensity in HL
In this video, Peter Borchmann, MD, University Hospital Cologne, Cologne, Germany, discusses the value of using PET-adapted study designs to guide treatment and de-escalate treatment intensity in patients with Hodgkin lymphoma (HL), as well as reduce the risk of anthracycline-associated severe delayed side effects. This interview took place at the 12th International Symposium on Hodgkin Lymphoma (ISHL12), held in Cologne, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
